LGALS9 and glioma: Solid tumors, including breast, head and neck, prostate, NSCLC, and glioma [267,277], express high levels of TIM-3 on T cells and Gal-9 on cancer cells, rendering TIM-3/Gal-9 binding a target of immunotherapy.